Eaton highlights potential of Tropine 3 for women with hot flashes

Eaton Scientific Systems, Ltd. ("Eaton" or the "Company") a wholly-owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to highlight the increasing international potential of Tropine 3 for the non-hormonal treatment for pre-menopausal, peri-menopausal, and post-menopausal women experiencing hot flashes.

"Menopause affects women all over the world, but according to recent research it actually appears to affect women in Asia and Latin America at a dramatically younger age along with greater and longer symptom prevalence," stated Michael Borkowski, CEO of Eaton Scientific.  "With this in mind, we intend to develop Tropine 3 to take advantage of potential global marketing and distribution opportunities."

Recent scientific research has indicated that women in the United States and Europe reach menopause at a median age ranging from 50.1 to 51.4 years.  This same research study concluded that in Latin America the median age of menopause was 43.8 to 53 years, and in Asia from 42.1 to 49.5 years.  Other large research studies also concluded that the frequency of menopause symptoms range from 36–50% of women in North America, up to 45–69% in Latin America, 22–63% in Asia, and 74% in Europe.

The earlier onset of menopause and increased prevalence of menopause symptoms outside of North America represents an important strategic opportunity to expand Tropine 3 awareness on a global scale.  The Company could potentially enter into business arrangements with established drug distribution organizations to accomplish this.